The U.S. Secretary of War, Pete Hegseth, declared on Wednesday the launch of a new screening initiative for identifying “testosterone deficiency” among military personnel. Hegseth emphasized the importance of ensuring troops can perform at their peak by undergoing these screenings annually if they are aged 30 or above. Service members below 30 have the option to volunteer for testing.
While addressing the troops in a social media video, Hegseth focused on the testing of male service members for hormone irregularities. This move aligns with other Trump administration officials advocating for increased accessibility to testosterone replacement therapies. However, Hegseth’s messaging, along with others, combines established scientific knowledge on hormones with broader, less substantiated claims.
When questioned about the objectives of this new policy, the Pentagon referenced Hegseth’s statements in the video stressing the necessity of keeping troops “strong, resilient, and capable” to meet the demands of modern warfare. Specific conditions or diseases targeted by the policy were not disclosed by the Pentagon. Hegseth clarified in his video that participation in testosterone replacement therapy would be voluntary.
The announcement faced criticism from Democrats, with many highlighting the previous Trump administration’s opposition to hormone therapy for transgender individuals serving in the military. Presently, transgender individuals are not allowed to enlist in the U.S. military due to an ongoing legal battle regarding the discharge of those already in active duty.
In recent years, there has been increased scrutiny on special operations troops, particularly U.S. navy SEALs, concerning their use of testosterone and similar substances for performance enhancement. Following the death of a SEAL recruit during training in 2022, revealing widespread drug use within the elite program, the U.S. navy initiated a drug-testing program targeting substances promoting muscle growth related to testosterone.
Hegseth emphasized that the new initiative aims to enhance troop performance without resorting to artificial enhancement. The Pentagon did not provide details on the research supporting this decision or whether female service members would undergo screenings for estrogen reduction during perimenopause.
Testosterone levels naturally decrease in men with age, affecting various aspects such as erectile dysfunction, libido, mood changes, and weight gain. The debate among experts continues on diagnosing and treating these issues through hormone replacement therapy.
In parallel, Health Secretary Robert F. Kennedy Jr. and other officials in the Trump administration are working to streamline the prescription process for testosterone. The Food and Drug Administration (FDA) recently proposed relaxing prescription limitations on testosterone products, which are currently indicated for men with hypogonadism, a condition characterized by significantly low testosterone levels.
While some advocate for testosterone as a means to maintain youthfulness, build muscle, and enhance cognitive function, medical professionals generally do not endorse these uses. Recent studies have highlighted potential benefits of testosterone for certain conditions while addressing concerns about its safety, particularly regarding heart health.
The FDA’s removal of a warning about heart attack and stroke risks associated with testosterone drugs last year reflects evolving perspectives on their safety. Studies have shown improvements in sexual function, muscle mass, strength, and bone density with testosterone therapy. However, medical guidelines caution against indiscriminate testosterone level testing, recommending discussions on therapy for men showing symptoms and confirmed low hormone levels on multiple tests.
Accurate testosterone testing is complex due to hormonal fluctuations throughout the day, necessitating morning fasting for reliable results.